Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity.

Webb J, Willette AA.

Neurobiol Aging. 2017 Feb;50:39-46. doi: 10.1016/j.neurobiolaging.2016.10.006. Epub 2016 Oct 13.

2.

Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.

Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, Bras J, Hersheson J, Stamelou M, Pittman AM, Noyce AJ, Mok KY, Opladen T, Kunstmann E, Hodecker S, Münchau A, Volkmann J, Samnick S, Sidle K, Nanji T, Sweeney MG, Houlden H, Batla A, Zecchinelli AL, Pezzoli G, Marotta G, Lees A, Alegria P, Krack P, Cormier-Dequaire F, Lesage S, Brice A, Heutink P, Gasser T, Lubbe SJ, Morris HR, Taba P, Koks S, Majounie E, Raphael Gibbs J, Singleton A, Hardy J, Klebe S, Bhatia KP, Wood NW; International Parkinson’s Disease Genomics Consortium and UCL-exomes consortium.

Brain. 2014 Sep;137(Pt 9):2480-92. doi: 10.1093/brain/awu179. Epub 2014 Jul 2.

3.

Association of GCH1 and MIR4697, but not SIPA1L2 and VPS13C polymorphisms, with Parkinson's disease in Taiwan.

Chen CM, Chen YC, Chiang MC, Fung HC, Chang KH, Lee-Chen GJ, Wu YR.

Neurobiol Aging. 2016 Mar;39:221.e1-5. doi: 10.1016/j.neurobiolaging.2015.12.016. Epub 2015 Dec 30.

PMID:
26804608
4.

GCH1 mutations in dopa-responsive dystonia and Parkinson's disease.

Yoshino H, Nishioka K, Li Y, Oji Y, Oyama G, Hatano T, Machida Y, Shimo Y, Hayashida A, Ikeda A, Mogushi K, Shibagaki Y, Hosaka A, Iwanaga H, Fujitake J, Ohi T, Miyazaki D, Sekijima Y, Oki M, Kusaka H, Fujimoto KI, Ugawa Y, Funayama M, Hattori N.

J Neurol. 2018 Aug;265(8):1860-1870. doi: 10.1007/s00415-018-8930-8. Epub 2018 Jun 14.

PMID:
29948246
5.

Low frequency of GCH1 and TH mutations in Parkinson's disease.

Rengmark A, Pihlstrøm L, Linder J, Forsgren L, Toft M.

Parkinsonism Relat Disord. 2016 Aug;29:109-11. doi: 10.1016/j.parkreldis.2016.05.010. Epub 2016 May 7.

PMID:
27185167
6.

Novel GCH1 variant in Dopa-responsive dystonia and Parkinson's disease.

Lewthwaite AJ, Lambert TD, Rolfe EB, Olgiati S, Quadri M, Simons EJ, Morrison KE, Bonifati V, Nicholl DJ.

Parkinsonism Relat Disord. 2015 Apr;21(4):394-7. doi: 10.1016/j.parkreldis.2015.01.004. Epub 2015 Jan 14.

7.

Association analyses of variants of SIPA1L2, MIR4697, GCH1, VPS13C, and DDRGK1 with Parkinson's disease in East Asians.

Zou M, Li R, Wang JY, Wang K, Wang YN, Li Y, Ji FX, Sun SN, Huang SS, Fan HH, Huang CP, Zhang X, Zhu JH.

Neurobiol Aging. 2018 Aug;68:159.e7-159.e14. doi: 10.1016/j.neurobiolaging.2018.03.005. Epub 2018 Mar 10.

PMID:
29622492
8.

Study of GCH1 and TH genes in Chinese patients with Parkinson's disease.

Yan YP, Zhang B, Shen T, Si XL, Guo ZY, Tian J, Xu CY, Zhang BR.

Neurobiol Aging. 2018 Aug;68:159.e3-159.e6. doi: 10.1016/j.neurobiolaging.2018.02.004. Epub 2018 Apr 5.

PMID:
29724574
9.

SIPA1L2, MIR4697, GCH1 and VPS13C loci and risk of Parkinson's diseases in Iranian population: A case-control study.

Safaralizadeh T, Jamshidi J, Esmaili Shandiz E, Movafagh A, Fazeli A, Emamalizadeh B, Manafi N, Taghavi S, Tafakhori A, Darvish H.

J Neurol Sci. 2016 Oct 15;369:1-4. doi: 10.1016/j.jns.2016.08.001. Epub 2016 Aug 2.

PMID:
27653855
10.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative.

JAMA Neurol. 2013 Oct;70(10):1277-87.

11.

Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.

Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, Kim KM, Yoon KY, Lee MC, Lee SB.

Ann Neurol. 1998 Jun;43(6):792-800.

PMID:
9629849
12.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative.

Acta Neuropathol. 2016 Jun;131(6):935-49. doi: 10.1007/s00401-016-1552-2. Epub 2016 Mar 28.

13.

Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.

van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WD.

Eur J Neurol. 2014 Mar;21(3):388-94. doi: 10.1111/ene.12176. Epub 2013 Apr 30.

PMID:
23631635
14.

Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI).

Nalls MA, Keller MF, Hernandez DG, Chen L, Stone DJ, Singleton AB; Parkinson's Progression Marker Initiative (PPMI) investigators.

Mov Disord. 2016 Jan;31(1):79-85. doi: 10.1002/mds.26374. Epub 2015 Aug 13.

15.

Association of four new candidate genetic variants with Parkinson's disease in a Han Chinese population.

Wang L, Cheng L, Li NN, Yu WJ, Sun XY, Peng R.

Am J Med Genet B Neuropsychiatr Genet. 2016 Apr;171B(3):342-7. doi: 10.1002/ajmg.b.32410. Epub 2015 Dec 17.

PMID:
26678010
16.

GCH1 in early-onset Parkinson's disease.

Cobb SA, Wider C, Ross OA, Mata IF, Adler CH, Rajput A, Rajput AH, Wu RM, Hauser R, Josephs KA, Carr J, Gwinn K, Heckman MG, Aasly JO, Lynch T, Uitti RJ, Wszolek ZK, Kapatos G, Farrer MJ.

Mov Disord. 2009 Oct 30;24(14):2070-5. doi: 10.1002/mds.22729.

PMID:
19735094
17.

Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.

Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, Aarsland D.

J Parkinsons Dis. 2015;5(4):783-92. doi: 10.3233/JPD-150682.

18.

Lack of reproducibility in re-evaluating associations between GCH1 polymorphisms and Parkinson's disease and isolated dystonia in an Australian case--control group.

Newman JR, Todorovic M, Silburn PA, Sutherland GT, Mellick GD.

Parkinsonism Relat Disord. 2014 Jun;20(6):668-70. doi: 10.1016/j.parkreldis.2014.02.014. Epub 2014 Mar 12. No abstract available.

PMID:
24674769
19.

Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients.

Erro R, Pappatà S, Amboni M, Vicidomini C, Longo K, Santangelo G, Picillo M, Vitale C, Moccia M, Giordano F, Brunetti A, Pellecchia MT, Salvatore M, Barone P.

Parkinsonism Relat Disord. 2012 Nov;18(9):1034-8. doi: 10.1016/j.parkreldis.2012.05.022. Epub 2012 Jul 11.

PMID:
22789824
20.

Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.

Rahmim A, Salimpour Y, Jain S, Blinder SA, Klyuzhin IS, Smith GS, Mari Z, Sossi V.

Neuroimage Clin. 2016 Feb 23;12:e1-e9. eCollection 2016.

Supplemental Content

Support Center